Cancer Chemotherapy and Pharmacology

, Volume 57, Issue 2, pp 145–154 | Cite as

Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient

  • David J. Adams
  • Miriam L. Wahl
  • James L. Flowers
  • Banalata Sen
  • Michael Colvin
  • Mark W. Dewhirst
  • Govindarajan Manikumar
  • Mansukh C. Wani
Original Article

Abstract

Human breast tumors often exist in an acidic and hypoxic microenvironment, which can promote resistance to radiation and chemotherapies. A tumor-selective pH gradient arises in these tumors which favors uptake and retention of drugs like camptothecin that are weak acids. We evaluated the effect of alkyl substitutions at the 7 position in seven CPTs with varying groups at the 10 position on modulation by acidic extracellular pH in three human breast cancer cell lines. Growth inhibition was assessed by propidium iodide staining of nucleic acids in human breast cancer cells cultured at either extracellular pH 6.8 or 7.4 that were (1) hormone-sensitive (MCF-7/wt), (2) hormone insensitive (MDA-MB-231), or (3) alkylator-resistant (MCF-7/4-hc). Over 10-fold pH modulation was observed in 7-halomethyl analogs of methylenedioxy-CPT and in 7-alkyl analogs of 10-amino-CPT. Of 39 analogs tested, the overall pattern of activity across breast tumor cell lines was similar with some notable exceptions. For example, 7-propyl-10-amino-CPT was modulated 16- to 20-fold by acidic extracellular pH in the MCF-7 cell lines, but only 6-fold in MDA-MB-231 cells. One mechanism that can contribute to pH modulation is enhanced cellular drug uptake and retention. In MCF-7/wt cells, uptake of 10-amino-CPT increased 4-fold, while retention increased over 10-fold at acidic extracellular pH. In addition, gene expression analysis of MCF-7/wt cells indicated that expression of a number of genes changed under acidic culture conditions, including down-regulation of the CPT efflux protein pump breast cancer resistance protein (BCRP). Interestingly, expression of topoisomerase I, the molecular target of CPT, was not affected by acidic growth conditions. These results highlight the importance of maintaining key features of tumor physiology in cell culture models used to study cancer biology and to discover and develop new anticancer drugs. While several substitutions at the 7 and 10 positions enhance potency, 7-halomethyl and 10-amino CPT analogs show selective activity at the acidic pH common to the microenvironment of most solid tumors.

Keywords

Camptothecin pH gradient Breast cancer Drug development Microarray 

Abbreviations

top1

Topoisomerase I

CPT

Camptothecin

MD or MDO

10,11-methylenedioxy

ED

10,11-ethylenedioxy

MeO

Methoxy

DFMD

Difluoromethylenedioxy

CMMDC

7-chloromethyl-10,11-methylenedioxy-camptothecin

SN-38

7-ethyl-10-hydroxy-camptothecin

References

  1. 1.
    Adams DJ, Dewhirst MW, Flowers JL, Gamcsik MP, Colvin OM, Manikumar G, Wani MC, Wall ME (2000) Camptothecin analogues with enhanced antitumor activity at acidic pH. Cancer Chemother Pharmacol 46:263–271CrossRefPubMedGoogle Scholar
  2. 2.
    Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson Strode J, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL, Latus LJ, Pommier Y, Burke TG (2000) The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970–3980CrossRefPubMedGoogle Scholar
  3. 3.
    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581CrossRefPubMedGoogle Scholar
  4. 4.
    Brown JM (1999) The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863–5870PubMedGoogle Scholar
  5. 5.
    Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62:1139–1147PubMedGoogle Scholar
  6. 6.
    Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ (2003) The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol 52:253–261CrossRefPubMedGoogle Scholar
  7. 7.
    Gamcsik MP, Kasibhatla MS, Adams DJ, Flowers JL, Colvin OM, Manikumar G, Wani M, Wall ME, Kohlhagen G, Pommier Y (2001) Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex. Mol Cancer Ther 1:11–20PubMedGoogle Scholar
  8. 8.
    Gerweck LE, Seetharaman K (1996) Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56:1194–1198PubMedGoogle Scholar
  9. 9.
    Giovanella B, Stehlin J, Wall M, Wani M, Nicholas A, Liu L, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046–1048PubMedCrossRefGoogle Scholar
  10. 10.
    Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V (2004) Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 6:R191–R198CrossRefPubMedGoogle Scholar
  11. 11.
    Hirabayashi N, Kim R, Nishiyama M, Aogi K, Saeki S, Toge T, Okada K (1992) Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues (abstract). Proc Am Assoc Cancer Res 33:436Google Scholar
  12. 12.
    Hohenberger P, Felgner C, Haensch W, Schlag PM (1998) Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat 48:97–106CrossRefPubMedGoogle Scholar
  13. 13.
    Husain I, Mohler JL, Seigler HF, Besterman JM (1994) Elevation of topoisomerase-I messenger-RNA, protein, and catalytic activity in human tumors—demonstration of tumor-type specificity and implications for cancer-chemotherapy. Cancer Res 54:539–546PubMedGoogle Scholar
  14. 14.
    Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465–1469PubMedGoogle Scholar
  15. 15.
    Kehrer DFS, Soepenberg O, Loos WJ, Verweij J, Sparreboom A (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drug 12:89–105CrossRefPubMedGoogle Scholar
  16. 16.
    Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders J, van der Kogel AJ, Riggins GJ (2001) Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337–1343CrossRefPubMedGoogle Scholar
  17. 17.
    Li TK, Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41:53–77CrossRefPubMedGoogle Scholar
  18. 18.
    Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207–1218CrossRefPubMedGoogle Scholar
  19. 19.
    Matsui S, Endo W, Wrzosek C, Haridas K, Seetharamulu P, Hausheer FH, Rustum YM (1999) Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications. Eur J Cancer 35:984–993CrossRefPubMedGoogle Scholar
  20. 20.
    Matsumoto Y, Fujiwara T, Nagao S (1995) Determinants of drug response in camptothecin-11 resistant cell lines. J Neurooncol 23:1–8CrossRefPubMedGoogle Scholar
  21. 21.
    Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima Y, Saijo N (1992) Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52:328–333PubMedGoogle Scholar
  22. 22.
    Pommier Y, Pourquier P, Fan Y, Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83–105PubMedGoogle Scholar
  23. 23.
    Potmesil M, Hsiang Y-H, Liu L et al (1988) Topoisomerase I (topo-I) and topoisomerase II (topo-II) levels in high and low grade lymphomas. Proc Am Assoc Cancer Res 29:176Google Scholar
  24. 24.
    Prescott DM, Charles HC, Poulson JM, Page RL, Thrall DE, Vujaskovic Z, Dewhirst MW (2000) The relationship between intracellular and extracellular pH in spontaneous canine tumors. Clin Cancer Res 6:2501–2505PubMedGoogle Scholar
  25. 25.
    Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ (1999) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80:1005–1011CrossRefPubMedGoogle Scholar
  26. 26.
    Raghunand N, Mahoney BP, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics I. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 66:1219–1229CrossRefPubMedGoogle Scholar
  27. 27.
    Runkel S, Wischnik A, Teubner J, Kaven E, Gaa J, Melchert F (1994) Oxygenation of mammary tumors as evaluated by ultrasound-guided computerized-pO2-histography. Adv Exp Med Biol 345:451–458PubMedGoogle Scholar
  28. 28.
    Sawyer TE, Bonner JA (1996) The interaction of buthionine sulphoximine (BSO) and the topoisomerase I inhibitor CPT-11. Br J Cancer Suppl 27:S109–S113PubMedGoogle Scholar
  29. 29.
    Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G (2002) Overexpression of hypoxia-inducible factor 1 alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837PubMedGoogle Scholar
  30. 30.
    Stubbs M, Bashford CL, Griffiths JR (2003) Understanding the tumor metabolic phenotype in the genomic era. Curr Mol Med 3:49–59PubMedCrossRefGoogle Scholar
  31. 31.
    Tannock I, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373–4384PubMedGoogle Scholar
  32. 32.
    Van der Zee A, Hollema H, DeJong S, Boonstra H, Gouw A, Willemse P, Zijlstra J, de Vries E (1991) P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51:5915–5920PubMedGoogle Scholar
  33. 33.
    Van Hattum AH, Pinedo HM, Schluper HM, Hausheer FH, Boven E (2000) New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 88:260–266CrossRefPubMedGoogle Scholar
  34. 34.
    Vaupel P, Schlenger K, Knoop C, Hockel M (1991) Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51:3316–3322PubMedGoogle Scholar
  35. 35.
    Vladu B, Woynarowski JM, Manikumar G, Wani MC, Wall ME, Von Hoff DD, Wadkins RM (2000) 7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents. Mol Pharmacol 57:243–251PubMedGoogle Scholar
  36. 36.
    Wachsberger PR, Landry J, Storck C, Davis K, MD OH, Owen CS, Leeper DB, Coss RA (1997) Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin. Int J Hyperthermia 13:251–255; discussion 257–259Google Scholar
  37. 37.
    Wahl M, Owen J, Burd R, Herlands R, Nogami S, Rodeck U, Berd D, Leeper D, Owen C (2002) Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1:617–628PubMedGoogle Scholar
  38. 38.
    Wahl ML, Pooler PM, Briand P, Leeper DB, Owen CS (2000) Intracellular pH regulation in a nonmalignant and a derived malignant human breast cell line. J Cell Physiol 183:373–380CrossRefPubMedGoogle Scholar
  39. 39.
    Wike-Hooley JL, Haveman J, Reinhold HS (1984) The Relevance of Tumor pH to the Treatment of Malignant Disease. Radiother Oncol 2:343–366PubMedCrossRefGoogle Scholar
  40. 40.
    Williams KJ, Cowen RL, Stratford IJ (2001) Hypoxia and oxidative stress in breast cancer-Tumour hypoxia—therapeutic considerations. Breast Cancer Res 3:328–331CrossRefPubMedGoogle Scholar
  41. 41.
    Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P (2002) Hypoxia as a target for combined modality treatments. Eur J Cancer 38:240–257CrossRefPubMedGoogle Scholar
  42. 42.
    Zunino F, Pratesi G (2004) Camptothecins in clinical development. Expert Opin Inv Drug 13:269–284CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • David J. Adams
    • 1
  • Miriam L. Wahl
    • 3
  • James L. Flowers
    • 1
  • Banalata Sen
    • 1
    • 5
  • Michael Colvin
    • 1
  • Mark W. Dewhirst
    • 2
  • Govindarajan Manikumar
    • 4
  • Mansukh C. Wani
    • 4
  1. 1.Departments of MedicineDuke University Medical CenterDurhamUSA
  2. 2.Departments of Radiation OncologyDuke University Medical CenterDurhamUSA
  3. 3.Departments of PathologyDuke University Medical CenterDurhamUSA
  4. 4. Research Triangle InstituteDurhamUSA
  5. 5. USEPADurhamUSA

Personalised recommendations